Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
Study sponsor: Cognition Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-03-04Actual
Enrollment · participants100Actual
Source updated2025-04-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.